Innovative Alpaca-Derived Psoriasis Treatment Shows Preclinical Promise
Inflammation and immunology company, Scinai Immunotherapeutics (Nasdaq: SCNI), has received encouraging results in a preclinical study of its anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.
Scinai’s alpaca-derived NanoAbs are designed to be administered locally to the dermis and are engineered to degrade in a way that should prevent systemic side effects. Study results suggest the potential for a highly efficacious, safer and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients.
Scinai anticipates results from an ex-vivo study in human psoriatic skin in Q4 2023 and in-vivo animal study results in early 2024.
Highlights
Scinai’s NanoAbs are alpaca‑derived recombinant variable domain of heavy-chain-only antibodies and are also known as nanobodies or VHH antibodies.
The company’s NanoAbs were tested in a 3D biologic skin model induced to express plaque psoriasis. Upon introduction of NanoAbs into the model (either topically or subcutaneously), standard molecular markers for psoriasis that are overexpressed in the disease (S100A7, CXCL1, and CCL20) were downregulated and outer skin layers regained normal appearance.
Scinai’s treatment is targeting mild psoriasis, which accounts for 50% of plaque psoriatic patients, has no safe, affordable biological drug available.
About Scinai
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com.
